These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21484283)

  • 1. A systematic review of the psychiatric side-effects of efavirenz.
    Kenedi CA; Goforth HW
    AIDS Behav; 2011 Nov; 15(8):1803-18. PubMed ID: 21484283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
    Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
    Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].
    Bary M; David F; Gasnault J; Kerneis H; Linard F; Longuet P; Pelissolo A; Ravaux I
    Med Mal Infect; 2004 Oct; 34(10):435-49. PubMed ID: 15747468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.
    Ibarra-Barrueta O; Palacios-Zabalza I; Mora-Atorrasagasti O; Mayo-Suarez J
    Ann Pharmacother; 2014 Jan; 48(1):145-8. PubMed ID: 24259633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
    Valeriano JJLS; Carvalho-Silva WHV; Coelho AVC; Moura RR; Arraes LC; Brandão LAC; Crovella S; Guimarães RL
    J Pharm Pharmacol; 2020 May; 72(5):719-727. PubMed ID: 32043598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of side effects with 2 doses of the HIV drug efavirenz.
    Ann Intern Med; 2009 Aug; 151(3):I24. PubMed ID: 19581632
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
    Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
    Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    Pedrol E; Llibre JM; Tasias M; Currán A; Guardiola JM; Deig E; Guelar A; Martínez-Madrid O; Tikhomirova L; Ramírez R;
    HIV Med; 2015 Nov; 16(10):628-34. PubMed ID: 26238151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apropos of atypical melancholia with Sustiva (efavirenz)].
    Lang JP; Halleguen O; Picard A; Lang JM; Danion JM
    Encephale; 2001; 27(3):290-3. PubMed ID: 11488260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
    Read TR; Carey D; Mallon P; Mijch A; Goodall R; Hudson F; Wand H; Emery S
    AIDS; 2009 Oct; 23(16):2222-3. PubMed ID: 19773634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.
    Sütterlin S; Vögele C; Gauggel S
    J Neuropsychiatry Clin Neurosci; 2010; 22(4):361-9. PubMed ID: 21037119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
    Ahmadi M; Khalili H; Abbasian L; Ghaeli P
    Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
    Gazzard B; Balkin A; Hill A
    AIDS Rev; 2010; 12(2):67-75. PubMed ID: 20571601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.